Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;97(24):e11115.
doi: 10.1097/MD.0000000000011115.

High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review

Dandan Xia  1 , Huiyu Wang, Runjie Wang, Chaoying Liu, Junying Xu
Affiliations
Review

High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review

Dandan Xia et al. Medicine (Baltimore). 2018 Jun.

Abstract

Rationale: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice.

Patient concerns: We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure.

Diagnoses: The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2).

Interventions: The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month.

Outcomes: The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved.

Lessons: Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2- advanced breast cancer with renal metastasis after SERMs failure.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Lung metastases before and following chemotherapy (red arrow)/fulvestrant (azure arrow).
Figure 2
Figure 2
Renal metastasis before and following chemotherapy (red arrow)/fulvestrant (azure arrow).
See this image and copyright information in PMC

References

    1. Sledge G, Mamounas E, Hortobagyi G, et al. Past, present and future challenges in breast cancer treatment. J Clin Oncol 2014;32:1979–86. - PMC - PubMed
    1. Huang H, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611–6. - PMC - PubMed
    1. Barrios C, Forbes J, Jonat W, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012;23:1378–86. - PMC - PubMed
    1. Powles J, Ashley S, Tidy A, et al. Twenty year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283–90. - PubMed
    1. Mustonen V, Pyrhonen S, Kellokumpu-Lehtinen L. Toremifene in the treatment of breast cancer. World J Clin Oncol 2014;5:393–405. - PMC - PubMed

MeSH terms